Loading
A phase 1/2 trial of TRI-611 in non-small-cell lung cancer and small-cell lung cancer, run by TRIANA Biomedicines, Inc., now recruiting.
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC is a phase 1/2 interventional study registered as NCT07491497 by TRIANA Biomedicines, Inc., with 160 participants planned, started 2026-03-11 and due to reach its primary completion in 2029-05-31. Interventions recorded: TRI-611. Conditions listed: ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.